Cancer remains among the leading causes of death worldwide. EUSA Pharma helps physicians and patients continue the fight against cancer by providing advanced treatment options.


Tivozanib is a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI): an oral, once-daily inhibitor of all three vascular endothelial growth factor (VEGF) receptors.Tivozanib is under review by the EMA for the first-line treatment of advanced renal cell carcinoma.